GlassScriptPhysician profile
Jeffrey W Benson
NPI 1679933584
$3,117.09
in general payments reported to CMS, 2019-2025
30 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $1,255 · 2023: $972 · 2024: $485 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $510.74 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $421.30 | 2022-2024 | Rybelsus, Ozempic, Tresiba |
| Pfizer INC. | $340.85 | 2021-2023 | |
| Abbvie INC. | $291.09 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $234.57 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $218.01 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $196.94 | 2023-2025 | Airsupra, Farxiga, Andexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.96 | 2021-2025 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $88.17 | 2021-2022 | |
| Exact Sciences Corporation | $86.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $79.28 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.02 | 2022 | |
| Dexcom, INC. | $55.83 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.30 | 2021-2023 | Jardiance |
| Axsome Therapeutics, INC. | $38.35 | 2024 | Auvelity |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $31.66 | 2022-2023 | Trintellix |
| Seqirus USA INC | $26.24 | 2025 | Fluad, Flucelvax |
| Amgen INC. | $26.21 | 2022-2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $25.56 | 2022-2023 | Xarelto |
| Sk Life Science, INC. | $19.03 | 2023 | |
| Amarin Pharma, INC. | $18.71 | 2022 | |
| Biogen, INC. | $17.19 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.50 | 2022 | |
| Halozyme INC | $16.24 | 2023 | |
| Phathom Pharmaceuticals, INC. | $16.22 | 2025 | Voquezna |
| Mylan Specialty L.P. | $16.12 | 2022 | |
| Currax Pharmaceuticals LLC | $15.75 | 2023 | Contrave |
| Alk-Abello, INC | $13.10 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.